Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Med Chem ; 20(25): 3174-85, 2013.
Article in English | MEDLINE | ID: mdl-23899207

ABSTRACT

The treatment for both leishmaniasis and trypanosomiasis, which are severe human infections caused by trypanosomatids belonging to Leishmania and Trypanosoma genera, respectively, is extremely limited because of concerns of toxicity and efficacy with the available anti-protozoan drugs, as well as the emergence of drug resistance. Consequently, the urgency for the discovery of new trypanosomatid targets and novel bioactive compounds is particularly necessary. In this context, the investigation of changes in parasite gene expression between drug resistant/sensitive strains and in the up-regulation of virulence-related genes in infective forms has brought to the fore the involvement of calpain-like proteins in several crucial pathophysiological processes performed by trypanosomatids. These studies were encouraged by the publication of the complete genome sequences of three human pathogenic trypanosomatids, Trypanosoma brucei, Trypanosoma cruzi and Leishmania major, which allowed in silico analyses that in turn directed the identification of numerous genes with interesting chemotherapeutic characteristics, including a large family of calpain-related proteins, in which to date 23 genes were assigned as calpains in T. brucei, 40 in T. cruzi and 33 in L. braziliensis. In the present review, we intend to add to these biochemical/biological reports the investigations performed upon the inhibitory capability of calpain inhibitors against human pathogenic trypanosomatids.


Subject(s)
Calpain/antagonists & inhibitors , Protease Inhibitors/therapeutic use , Protozoan Proteins/antagonists & inhibitors , Trypanosomiasis/drug therapy , Calpain/metabolism , Humans , Peptides/chemistry , Peptides/pharmacology , Peptides/therapeutic use , Protease Inhibitors/pharmacology , Protozoan Proteins/metabolism , Trypanosoma/drug effects , Trypanosoma/enzymology , Trypanosomiasis/parasitology
2.
Parasitology ; 138(8): 960-8, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21679488

ABSTRACT

Recent have shown the relationship between Ecto-Nucleoside-Triphosphate-Diphosphohydrolases (Ecto-NTPDases or ecto-nucleotidases) and virulence and infectivity in trypanosomatids. In this work, the inhibition of the ecto-ATPase activities and promastigote growth of Leishmania amazonensis by CrATP was characterized. Furthermore, this compound was used to investigate the role of ecto-nucleotidase in the interaction of L. amazonensis with resident peritoneal macrophages obtained from BALB/c mice. CrATP partially inhibits the ecto-ATPase activity, presenting Ki values of 575·7±199·1 and 383·5±79·0 µm, in the presence or absence of 5 mm MgCl2, respectively. The apparent Kms for ATP (2·9±0·5 mm to Mg2+-dependent ecto-ATPase and 0·4±0·2 mm to Mg2+-independent ecto-ATPase activities) are not significantly altered by CrATP, suggesting a reversible non-competitive inhibition of both enzymes. When CrATP was added to the cultivation medium at 500 µm, it drastically inhibited the cellular growth. The interaction of promastigote forms of L. amazonensis with BALB/c peritoneal macrophages is strongly affected by CrATP. When the parasites were treated with 500 µm CrATP before interacting with macrophages, the adhesion and endocytic indices were strongly reduced to 53·0±14·8% and 39·8±1·1%, respectively. These results indicate that ecto-nucleotidase plays an important role in the infection process caused by Leishmania amazonensis.


Subject(s)
Adenosine Triphosphatases/metabolism , Adenosine Triphosphate/pharmacology , Leishmania mexicana/drug effects , Leishmania mexicana/enzymology , Leishmaniasis/parasitology , Macrophages, Peritoneal/drug effects , Adenosine Triphosphatases/antagonists & inhibitors , Adenosine Triphosphatases/drug effects , Adenosine Triphosphate/chemical synthesis , Animals , Dose-Response Relationship, Drug , Host-Parasite Interactions , Leishmania mexicana/growth & development , Leishmania mexicana/pathogenicity , Macrophages, Peritoneal/parasitology , Mice , Mice, Inbred BALB C , Virulence/drug effects
3.
Parasitology ; 136(4): 433-41, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19250597

ABSTRACT

In this paper, we aimed to explore the effects of the calpain inhibitor III (MDL28170) and to detect calpain-like molecules (CALPs) in epimastigote forms of Trypanosoma cruzi isolate Dm28c. MDL28170 at 70 microM promoted a powerful reduction in the growth rate after 48 h. The IC50 value was calculated to be 31.7 microM. This inhibitor promoted an increase in the cellular volume, but not cell lysis, resulting in a trypanostatic effect. T. cruzi CALPs presented a strong cross-reactivity with anti-Drosophila melanogaster calpain and anti-cytoskeleton-associated protein from Trypanosoma brucei antibodies, and labelling was found mainly intracellularly. Furthermore, an 80 kDa reactive protein was detected by Western blotting assays. No significant cross-reactivity was found with anti-human brain calpain antibody. The expression of CALPs was decreased in cells kept for long periods in axenic cultures in comparison to a strain recently isolated from mice, as well as in MDL28170-treated cells, the latter being paralleled by an increased expression of cruzipain. Different levels of CALPs expression were also detected in distinct phylogenetic lineages, like Y strain (lineage TcII), Dm28c (lineage TcI) [corrected] and INPA6147 strain (Z3 zymodeme). These results may contribute for the investigation of the functions of CALPs in trypanosomatids.


Subject(s)
Calpain/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Dipeptides/pharmacology , Protozoan Proteins/metabolism , Trypanosoma cruzi , Animals , Antibodies, Protozoan/immunology , Calpain/chemistry , Calpain/genetics , Calpain/immunology , Gene Expression Regulation , Humans , Mice , Protozoan Proteins/chemistry , Protozoan Proteins/genetics , Protozoan Proteins/immunology , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology , Trypanosoma cruzi/growth & development , Trypanosoma cruzi/immunology
SELECTION OF CITATIONS
SEARCH DETAIL